Targeting the Hedgehog pathway in cancer

Area of Science:

• Molecular Biology
• Developmental Biology
• Oncology

Background:

• The Hedgehog (Hh) signaling pathway is crucial for vertebrate embryonic development, controlling cell maintenance, differentiation, polarity, and proliferation.
• Aberrant Hh pathway activation is linked to tumorigenesis in basal cell carcinomas and medulloblastoma, and also observed in other cancers like brain, gastrointestinal, lung, breast, and prostate.
• Recent findings indicate paracrine Hh signaling promotes tumorigenesis and that the pathway regulates cancer stem cell proliferation and tumor invasiveness.

Purpose of the Study:

• To review the molecular mechanisms of Hh signaling.
• To discuss the role of Hh pathway activation in human cancers.
• To explore the clinical development of Hh pathway inhibitors as cancer therapeutics.

Main Methods:

• Review of molecular basis of Hh signaling.
• Analysis of Hh pathway activation in various human cancers.
• Discussion of clinical development of Hh pathway inhibitors.

Main Results:

• The Hh pathway is a key regulator in embryonic development and is inappropriately activated in numerous human cancers.
• Targeted inhibition of Hh signaling presents a potential therapeutic strategy for cancer treatment and prevention.
• The Hh pathway inhibitor GDC-0449 has shown promising efficacy and safety in early clinical trials for basal cell carcinoma and medulloblastoma.

Conclusions:

• Inhibition of the Hh pathway is a promising therapeutic strategy for various human cancers.
• The development of specific Hh pathway inhibitors has significant implications for novel cancer treatments.
• GDC-0449 is a leading Hh pathway inhibitor undergoing clinical evaluation with positive initial results.